Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

News Daily News

Angiogram-Derived Functional Tests Pre-TAVI: Simpler, Yes, but Warranted?

Michael O'Riordan

September 21, 2023

News Features

Chaos and Questions: New Public-Access Policies Put Journals in Flux

Michael O'Riordan

August 14, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2023

Caitlin E. Cox

February 01, 2023

News Opinion CV Team Dispatch

November 2022 News Roundup

L.A. McKeown

November 01, 2022

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

Todd Neale

October 14, 2021

News Daily News

New Advanced Training Outlined for Future Vascular Medicine Specialists

Michael O'Riordan

January 21, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Todd Neale

October 21, 2020

Advertisement

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

AHA Selects 2023’s Leading Cardiovascular Research

Angiogram-Derived Functional Tests Pre-TAVI: Simpler, Yes, but Warranted?

Chaos and Questions: New Public-Access Policies Put Journals in Flux

TCTMD’s Top 10 Most Popular Stories for January 2023

November 2022 News Roundup

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Half-Dose DOAC May Be a Good Post-Watchman Option

New Advanced Training Outlined for Future Vascular Medicine Specialists

Funding the Future: How Industry Support for CV Trials Could Evolve

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content